Babar Bashir, Executive Director of Clinical Development in Hematology Oncology at Incyte, shared on LinkedIn:
“I’m happy to share that I’ve stepped into a new role as Executive Director of Clinical Development in Hematology Oncology at Incyte! I’m looking forward to working with the outstanding team led by Ekaterine Asatiani.
I’m deeply grateful to my colleagues, mentors, and patients at Jefferson Health who shaped my path. While I’ll miss direct patient care, I’m committed to channeling the same energy into bringing novel therapies to patients with cancer, particularly GI cancers, where so much unmet need remains.
I look forward to partenering with my oncology colleagues across the world toward that shared goal.”
About Incyte
Incyte is a global biopharmaceutical company headquartered in Wilmington, Delaware, focused on the discovery, development and commercialization of innovative medicines for patients with significant unmet medical needs. Its research and development activities span three core therapeutic areas: hematology, oncology, and inflammation and autoimmunity, including dermatology. In oncology and hematology, Incyte focuses on advancing treatments for myeloproliferative neoplasms, hematologic malignancies, graft-versus-host disease and solid tumors.
Through continued investment in scientific research and clinical development, Incyte aims to translate scientific discoveries into meaningful advances in patient care.